Micreos Pockets €12m For Staphefeckt Products

Antibacterial-focused Micreos has pocketed €12m for the global development of its antibacterial lysin technology, Endolysin Staphefeckt, as a prescription product to suppress Staphylococcus aureus on the skin of individuals with eczema, rosacea and acne.